SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes

被引：4

作者：

Aguilera, Ximena ^{[1
]}

Hormazabal, Juan ^{[2
]}

Vial, Cecilia ^{[2
]}

Jimena Cortes, Lina ^{[2
]}

Gonzalez, Claudia ^{[1
]}

Rubilar, Paola ^{[1
]}

Apablaza, Mauricio ^{[3
]}

Ramirez-Santana, Muriel ^{[4
]}

Icaza, Gloria ^{[5
]}

Nunez-Franz, Loreto ^{[6
]}

Castillo-Laborde, Carla ^{[1
]}

Ramirez-Riffo, Carolina ^{[2
]}

Perez, Claudia ^{[7
]}

Quezada-Gate, Ruben ^{[4
]}

Said, Macarena ^{[6
]}

Vial, Pablo ^{[2
,8
]}

机构：

[1] Clin Alemana Univ Desarrollo, Ctr Epidemiol & Polit Salud, Fac Med, Av Plaza 680, Santiago 7610658, Chile

[2] Clin Alemana Univ Desarrollo, Inst Ciencias & Innovac Med, Fac Med, Av Plaza 680, Santiago 7610658, Chile

[3] Univ Desarrollo, Fac Gobierno, Av Plaza 680, Santiago 7610658, Chile

[4] Univ Catolica Norte, Fac Med, Publ Hlth Dept, Larrondo 1281, Coquimbo 1780000, Chile

[5] Univ Talca, Inst Matemat, Ave Uno Poniente 1141, Talca 3460000, Chile

[6] Univ Talca, Fac Ciencias Salud, Dept Salud Publ, Ave Uno Poniente 1141, Talca 3460000, Chile

[7] Clin Alemana Univ Desarrollo, Fac Med, Escuela Enfermeria, Av Plaza 680, Santiago 7610658, Chile

[8] Clin Alemana Santiago, Ave Vitacura 5951, Santiago 7650568, Chile

来源：

VACCINES | 2022年 / 10卷 / 07期

关键词：

neutralizing antibodies; vaccines; BNT162b2; CoronaVac; AZD1222; COVID-19; SARS-CoV-2; cross-sectional design; vaccine-preventable diseases; viruses; COVID-19; VACCINES; BNT162B2;

D O I：

10.3390/vaccines10071051

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.

引用

页数：7

共 50 条

[41] An original multiplex method to assess five different SARS-CoV-2 antibodies
Favresse, Julien
Brauner, Jonathan
Bodart, Nicolas
Vigneron, Alain
Roisin, Sandrine
Melchionda, Sabrina
Douxfils, Jonathan
Ocmant, Annick
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2021, 59 (05) : 971 - 978
[42] Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies
Sharun, Khan
Tiwari, Ruchi
Dhama, Kuldeep
Emran, Talha Bin
Rabaan, Ali A.
Al Mutair, Abbas
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (10) : 3491 - 3494
[43] Clinical Assessment of SARS-CoV-2 Antibodies in Oral Fluids Following Infection and Vaccination
Heaney, Christopher D.
Hempel, Heidi
Derosa, Kate L.
Pinto, Ligia A.
Mantis, Nicholas J.
CLINICAL CHEMISTRY, 2024, 70 (04) : 589 - 596
[44] Socioeconomic Differences in SARS-CoV-2 Infection and Vaccination in Germany: A Seroepidemiological Study After One Year of COVID-19 Vaccination Campaign
Bartig, Susanne
Beese, Florian
Wachtler, Benjamin
Grabka, Markus M.
Mercuri, Elisabetta
Schmid, Lorenz
Schmid-Kuepke, Nora Katharina
Schranz, Madlen
Gossner, Laura
Niehues, Wenke
Zinn, Sabine
Poethko-Mueller, Christina
Schaade, Lars
Hoevener, Claudia
Goesswald, Antje
Hoebel, Jens
INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2023, 68
[45] SARS-CoV-2 Antibodies Detected in Mother's Milk Post-Vaccination
Baird, Jill K.
Jensen, Shawn M.
Urba, Walter J.
Fox, Bernard A.
Baird, Jason R.
JOURNAL OF HUMAN LACTATION, 2021, 37 (03) : 492 - 498
[46] mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Stamatatos, Leonidas
Czartoski, Julie
Wan, Yu-Hsin
Homad, Leah J.
Rubin, Vanessa
Glantz, Hayley
Neradilek, Moni
Seydoux, Emilie
Jennewein, Madeleine F.
MacCamy, Anna J.
Feng, Junli
Mize, Gregory
De Rosa, Stephen C.
Finzi, Andres
Lemos, Maria P.
Cohen, Kristen W.
Moodie, Zoe
McElrath, M. Juliana
McGuire, Andrew T.
SCIENCE, 2021, 372 (6549) : 1413 - +
[47] Lymphocyte Subpopulations Associated with Neutralizing Antibody Levels of SARS-CoV-2 for COVID-19 Vaccination
Huang, Wan-Ting
Weng, Shao-Wen
Tzeng, Hong-Tai
Yen, Feng-Chun
Chiang, Yu-Shao
You, Huey-Ling
VACCINES, 2022, 10 (09)
[48] Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines
Hromic-Jahjefendic, Altijana
Lundstrom, Kenneth
Adilovic, Muhamed
Aljabali, Alaa A. A.
Tambuwala, Murtaza M.
Serrano-Aroca, Angel
Uversky, Vladimir N.
AUTOIMMUNITY REVIEWS, 2024, 23 (03)
[49] Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination
Graninger, Marianne
Camp, Jeremy V.
Aberle, Stephan W.
Traugott, Marianna T.
Hoepler, Wolfgang
Puchhammer-Stoeckl, Elisabeth
Weseslindtner, Lukas
Zoufaly, Alexander
Aberle, Judith H.
Stiasny, Karin
FRONTIERS IN IMMUNOLOGY, 2022, 13
[50] SARS-CoV-2 antibody response eight months after vaccination with mRNA vaccines. Influence of prior SARS-CoV-2 exposure
Fernando Garcia-Cruces-Mendeza, Jesus
Corral-Gudino, Luis
Piedad Del-Amo-Merino, Maria
Maria Eiros-Bouza, Jose
Dominguez-Gil Gonzalez, Marta
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2022, 97 : 113 - 115

← 1 2 3 4 5 →